Lipoprotein apheresis: an established therapeutic modality for homozygous familial hypercholesterolemia patients refractory to PCSK9 inhibitors: a case report and literature review.

MLA

Guan, Mingjing, et al. “Lipoprotein Apheresis: An Established Therapeutic Modality for Homozygous Familial Hypercholesterolemia Patients Refractory to PCSK9 Inhibitors: A Case Report and Literature Review.” Thrombosis Journal, vol. 22, no. 1, Oct. 2024, pp. 1–8. EBSCOhost, https://doi.org/10.1186/s12959-024-00657-w.

APA

Guan, M., Wang, H., Wang, F., Liang, S., Ling, L., Wang, B., & Zhang, L. (2024). Lipoprotein apheresis: an established therapeutic modality for homozygous familial hypercholesterolemia patients refractory to PCSK9 inhibitors: a case report and literature review. Thrombosis Journal, 22(1), 1–8. https://doi.org/10.1186/s12959-024-00657-w

Chicago

Guan, Mingjing, Hao Wang, Fang Wang, Shichu Liang, Li Ling, Bo Wang, and Ling Zhang. 2024. “Lipoprotein Apheresis: An Established Therapeutic Modality for Homozygous Familial Hypercholesterolemia Patients Refractory to PCSK9 Inhibitors: A Case Report and Literature Review.” Thrombosis Journal 22 (1): 1–8. doi:10.1186/s12959-024-00657-w.